- Home
- ARVN
ARVN
Arvinas Inc.
as 03-28-2025 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.2B | IPO Year: | 2018 |
| Target Price: | $34.42 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.53 - $41.34 | Next Earning Date: | 05-06-2025 |
| Revenue: | $263,399,999 | Revenue Growth: | 235.54% |
| Revenue Growth (this year): | -18.77% | Revenue Growth (next year): | 7.99% |
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Berkowitz Noah | ARVN | Chief Medical Officer | Mar 18 '25 | Sell | $8.59 | 8,658 | $74,372.22 | 110,023 | |
| Houston John G | ARVN | President and CEO | Feb 24 '25 | Sell | $16.65 | 31,338 | $523,880.70 | 1,157,480 | |
| Taylor Ian | ARVN | President, R&D | Feb 24 '25 | Sell | $16.65 | 9,020 | $150,752.20 | 160,785 | |
| Loomis David K | ARVN | Chief Accounting Officer | Feb 24 '25 | Sell | $16.75 | 1,214 | $20,334.50 | 18,863 | |
| Cacace Angela M | ARVN | Chief Scientific Officer | Feb 24 '25 | Sell | $16.65 | 4,207 | $70,238.05 | 98,377 |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Zacks
10 days ago
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Insider Monkey
11 days ago
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?
Zacks
12 days ago
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
Zacks
12 days ago
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
TipRanks
15 days ago
Biotech Alert: Searches spiking for these stocks today
Zacks
15 days ago
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Zacks
16 days ago
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.